These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28679024)

  • 21. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
    Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
    J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
    Miller AM; Shah RH; Pentsova EI; Pourmaleki M; Briggs S; Distefano N; Zheng Y; Skakodub A; Mehta SA; Campos C; Hsieh WY; Selcuklu SD; Ling L; Meng F; Jing X; Samoila A; Bale TA; Tsui DWY; Grommes C; Viale A; Souweidane MM; Tabar V; Brennan CW; Reiner AS; Rosenblum M; Panageas KS; DeAngelis LM; Young RJ; Berger MF; Mellinghoff IK
    Nature; 2019 Jan; 565(7741):654-658. PubMed ID: 30675060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
    Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
    AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
    Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1 mutation detection by droplet digital PCR in glioma.
    Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP
    Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
    Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
    J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
    Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
    Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
    Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
    Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
    Taylor JW; Chi AS; Cahill DP
    Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
    Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
    J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.
    Oktay Y; Ülgen E; Can Ö; Akyerli CB; Yüksel Ş; Erdemgil Y; Durası IM; Henegariu OI; Nanni EP; Selevsek N; Grossmann J; Erson-Omay EZ; Bai H; Gupta M; Lee W; Turcan Ş; Özpınar A; Huse JT; Sav MA; Flanagan A; Günel M; Sezerman OU; Yakıcıer MC; Pamir MN; Özduman K
    Sci Rep; 2016 Jun; 6():27569. PubMed ID: 27282637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.